中国现代神经疾病杂志 ›› 2012, Vol. 12 ›› Issue (6): 641-644. doi: 10.3969/j.issn.1672-6731.2012.06.003

• 专题讲座 • 上一篇    下一篇

2 Current concepts in glioblastoma imaging

George Alexiou1, Spyridon Tsiouris2, Haralabos Bougias2, Spyridon Voulgaris1, Andreas Fotopoulos2   

  1. 1 Department of Neurosurgery, University Hospital of Ioannina, Ioannina, Greece
    2 Department of Nuclear Medicine, University Hospital of Ioannina, Ioannina, Greece
  • 发布日期:2012-12-21
  • 通讯作者: George Alexiou (Email: alexiougrg@yahoo.gr; Cc email: alexiougr@gmail.com)

Current concepts in glioblastoma imaging

George Alexiou1, Spyridon Tsiouris2, Haralabos Bougias2, Spyridon Voulgaris1, Andreas Fotopoulos2   

  1. 1 Department of Neurosurgery, University Hospital of Ioannina, Ioannina, Greece
    2 Department of Nuclear Medicine, University Hospital of Ioannina, Ioannina, Greece
  • Published:2012-12-21
  • Contact: George Alexiou (Email: alexiougrg@yahoo.gr; Cc email: alexiougr@gmail.com)

摘要: Glioblastoma (GBM, WHO grade Ⅳ) is the most common and the most malignant primary brain tumor occurring during adulthood, with an annual incidence of 5 cases per 100 000. Treatment involves surgical resection, followed by radiotherapy and concomitant and adjuvant temozolomide. Despite multimodality treatment, the median survival time is 15 months. Herewith we discuss the value of neuroimaging in differentiating GBM from other types of brain tumors, in guiding tumor
biopsy, in making non-invasive assessment of tumor's aggressiveness, in estimating overall prognosis, in differentiating treatment-induced brain necrosis from tumor recurrence and in assessing response to treatment.

关键词: Glioblastoma, Magnetic resonance imaging, Tomography, emission-computed, single-photon, Tomography, emission-computed, Chemotherapy, adjuvant, Radiotherapy

Abstract: Glioblastoma (GBM, WHO grade Ⅳ) is the most common and the most malignant primary brain tumor occurring during adulthood, with an annual incidence of 5 cases per 100 000. Treatment involves surgical resection, followed by radiotherapy and concomitant and adjuvant temozolomide. Despite multimodality treatment, the median survival time is 15 months. Herewith we discuss the value of neuroimaging in differentiating GBM from other types of brain tumors, in guiding tumor
biopsy, in making non-invasive assessment of tumor's aggressiveness, in estimating overall prognosis, in differentiating treatment-induced brain necrosis from tumor recurrence and in assessing response to treatment.

Key words: Glioblastoma, Magnetic resonance imaging, Tomography, emission-computed, single-photon, Tomography, emission-computed, Chemotherapy, adjuvant, Radiotherapy